Herpes Zoster: An Insight Review on Virulence and Diagnosis

Herpes zoster virus (HZV) is a serious public health concern because of its high incidence and substantial morbidity, caused by the reactivation of latent varicella-zoster virus (VZV). The virus develops a latency stage in the cranial nerve ganglia and dorsal root after the first infection, and its reactivation is closely linked to immunosuppression and ageing. Herpes zoster clinically causes a painful vesicular rash that is limited to a dermatome; nevertheless, comorbidities such as neurological diseases, postherpetic neuralgia, and ocular involvement add to the long-term burden of the disease. Influential in regulating viral reactivation is the immunological response, and both innate and adaptive immunity are essential for preventing viral propagation. While early detection has been improved by developments in molecular diagnostics, such as PCR-based techniques, antiviral medications, and analgesic approaches continue to be the cornerstones of treatment. These methods, however, are not very effective at preventing long-term issues. On the other hand, the incidence and severity of herpes zoster have decreased significantly with the introduction of live-attenuated and recombinant subunit vaccines, with prevention becoming the most effective control strategy. Characterization of viral latency, identification of the parameters for virulence, and the construction of superior vaccines and therapeutic regimens are the major goals for future studies. Epidemiology, pathophysiology, clinical presentation, diagnosis, management, and prevention of the herpes zoster virus are the major points highlighted in this article.